Plasma-derived product · developed by Kamada
Kamada Anti-SARS-CoV-2 is an immune gamma globulin preparation manufactured from convalescent plasma of recovered COVID-19 patients, purified by the developer's proprietary methods. It is studied in COVID-19 and viral pneumonia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04550325 | Phase 1/2 | Covid19 | Completed | KMDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Covid19Pneumonia, Viral
Updated Oct 18, 2026. Something wrong or missing? Report it on the KMDA page.
See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KMDA catalysts and pipeline →